Editorial: Antibody-drug conjugates in solid and hematologic malignancies.
作者信息
Saleh Khalil, Raman Ayush, Zanoni Michele
机构信息
International Department, Gustave Roussy Cancer Campus, Villejuif, France.
National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, United States.
出版信息
Front Immunol. 2025 Aug 14;16:1662653. doi: 10.3389/fimmu.2025.1662653. eCollection 2025.
Abstract
摘要
相似文献
1
Editorial: Antibody-drug conjugates in solid and hematologic malignancies.社论：实体瘤和血液系统恶性肿瘤中的抗体药物偶联物
Front Immunol. 2025 Aug 14;16:1662653. doi: 10.3389/fimmu.2025.1662653. eCollection 2025.
2
Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.实体瘤肿瘤学中的抗体药物偶联物：靶向有效载荷带来的疗效收获。
Pharmaceutics. 2023 Aug 19;15(8):2160. doi: 10.3390/pharmaceutics15082160.
3
Antibody-drug conjugates in solid tumors; new strategy for cancer therapy.抗体药物偶联物在实体瘤中的应用；癌症治疗的新策略。
Jpn J Clin Oncol. 2024 Aug 14;54(8):837-846. doi: 10.1093/jjco/hyae054.
4
Integrated strategy for biotransformation of antibody-drug conjugates and multidimensional interpretation via high-resolution mass spectrometry.抗体药物偶联物生物转化的综合策略及通过高分辨率质谱进行的多维解读
Drug Metab Dispos. 2025 Jun;53(6):100081. doi: 10.1016/j.dmd.2025.100081. Epub 2025 Apr 22.
5
Anti-HER2, High-DAR Antibody Fragment-Drug Conjugates with a Glucuronide-Based MMAE Linker-Payload Demonstrate Superior Efficacy over IgG-Based ADCs.具有基于葡萄糖醛酸的MMAE连接子-载荷的抗HER2高DAR抗体片段-药物偶联物显示出优于基于IgG的ADC的疗效。
Mol Cancer Ther. 2025 Sep 2;24(9):1295-1307. doi: 10.1158/1535-7163.MCT-24-1182.
6
Update of antibody-drug conjugates for hematological malignancies.抗体偶联药物在血液系统恶性肿瘤中的研究进展。
Curr Opin Oncol. 2024 Sep 1;36(5):430-436. doi: 10.1097/CCO.0000000000001065. Epub 2024 Jun 28.
7
A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs.一种双payload双特异性ADC比单payload双特异性ADC具有更高的效力和疗效。
Pharmaceutics. 2025 Jul 25;17(8):967. doi: 10.3390/pharmaceutics17080967.
8
Antibody-drug conjugates in breast cancer: From therapeutic and immune activation mechanisms to resistance prevention.乳腺癌中的抗体药物偶联物：从治疗和免疫激活机制到耐药性预防
Int Rev Immunol. 2025 Aug 19:1-23. doi: 10.1080/08830185.2025.2545364.
9
Innovations in cancer immunotherapy with PD-1 antibody-drug conjugates and their antitumor mechanisms.PD-1抗体药物偶联物在癌症免疫治疗中的创新及其抗肿瘤机制。
Biomed Pharmacother. 2025 Aug 29;191:118517. doi: 10.1016/j.biopha.2025.118517.
10
Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates.拓扑异构酶I抑制剂在间充质恶性肿瘤治疗中的当前作用及其作为肉瘤特异性抗体药物偶联物有效载荷的潜在未来应用。
Oncol Res Treat. 2024;47(1-2):18-41. doi: 10.1159/000535491. Epub 2023 Nov 28.
本文引用的文献
1
Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals.抗体药物偶联物（ADCs）：当前及未来的生物制药
J Hematol Oncol. 2025 Apr 30;18(1):51. doi: 10.1186/s13045-025-01704-3.
2
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.戈沙妥珠单抗治疗晚期尿路上皮癌：III期随机试验TROPiCS-04
Ann Oncol. 2025 May;36(5):561-571. doi: 10.1016/j.annonc.2025.01.011. Epub 2025 Feb 11.
3
Update of antibody-drug conjugates for hematological malignancies.抗体偶联药物在血液系统恶性肿瘤中的研究进展。
Curr Opin Oncol. 2024 Sep 1;36(5):430-436. doi: 10.1097/CCO.0000000000001065. Epub 2024 Jun 28.
4
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.恩福妥单抗Vedotin 联合帕博利珠单抗治疗未经治疗的晚期尿路上皮癌。
N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117.
5
Antibody-drug conjugates for urothelial carcinoma.抗体药物偶联物治疗尿路上皮癌。
Urol Oncol. 2023 Oct;41(10):420-428. doi: 10.1016/j.urolonc.2023.06.006. Epub 2023 Jul 6.
6
Antibody-Drug Conjugates in Gynecologic Cancer.抗体药物偶联物在妇科癌症中的应用
Am Soc Clin Oncol Educ Book. 2023 May;43:e390772. doi: 10.1200/EDBK_390772.
7
Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.靶向癌症的抗体药物偶联物和双特异性抗体：点击化学的应用
Arch Pharm Res. 2023 Mar;46(3):131-148. doi: 10.1007/s12272-023-01433-6. Epub 2023 Mar 6.
8
The therapeutic window of antibody drug conjugates: A dogma in need of revision.抗体药物偶联物的治疗窗口：一个需要修正的教条。
Cancer Cell. 2022 Nov 14;40(11):1255-1263. doi: 10.1016/j.ccell.2022.09.016. Epub 2022 Oct 13.
9
TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer.TROP2（滋养细胞表面抗原 2）：乳腺癌的药物靶点。
Expert Opin Ther Targets. 2022 Jul;26(7):593-602. doi: 10.1080/14728222.2022.2113513. Epub 2022 Aug 19.
Zotero 插件